Home

Content about psoriasis

01.05.10
Phase 2 study evaluating VBL Therapeutics' lead compound VB-201 initiated

VBL Therapeutics today announced the initiation of a Phase 2 efficacy and safety study evaluating lead compound VB-201 for the treatment of patients with psoriasis. VB-201 is poised to be a first-in-class, orally-administered immune response modifier expected to reduce inflammation in a broad range of conditions such as psoriasis.

12.01.09
Positive data from Provectus Pharmaceuticals' psoriasis and atopic dermatitis trials

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced preliminary data for the company’s PH-10 Phase 2 clinical trial for Psoriasis as well as for its Phase 2 clinical trial for Atopic Dermatitis.

07.02.09
Examining The Risk Of Tuberculosis From Arthritis Medication

Treatment with anti-tumor necrosis factor (TNF) agents is recognized as a risk factor for tuberculosis (TB) in patients with immune-mediated inflammatory diseases such as rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, psoriatic arthritis and psoriasis. Most TB cases develop as a result of reactivation of a latent TB infection, and health authorities worldwide recommend screening for latent TB and treating patients before initiating anti-TNF treatment.

06.15.09
Skin disease psoriasis associated with cardiovascular disease and increased mortality

The skin disease psoriasis is associated with atherosclerosis (a buildup of plaque in the arteries) characterized by an increased prevalence of ischemic heart disease, cerebrovascular disease, peripheral artery disease and an increased risk of death, according to a report in the June issue of Archives of Dermatology.

05.07.09
Home versus outpatient ultraviolet B phototherapy for mild to severe psoriasis

For patients with psoriasis, treatment with ultraviolet B (UVB) at home is as effective and as safe as conventional hospital based phototherapy, concludes a study published on bmj.com today.

04.30.09
Research looks at UVB therapy for psoriasis

Ultraviolet light is a proven treatment for psoriasis, one of humanity's oldest known diseases.

04.08.09
Trial of new biologic agent to treat psoriatic arthritis

Psoriatic arthritis affects about 11 percent of patients with psoriasis.

03.25.09
Discovery of 'master regulator' gene for skin development

Researchers at Oregon State University have found one gene in the human body that appears to be a master regulator for skin development, in research that could help address everything from skin diseases such as eczema or psoriasis to the wrinkling of skin as people age.